This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Intocell, Inc., Y-Biologics Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 8 
1 out of 12 Years Active: 2024
Title: Yosup Rew: A Pioneer in Antibody-Drug Conjugates
Introduction
Yosup Rew, an innovative inventor based in Daejeon, South Korea, has made significant contributions to the field of biotechnology. With one patent to his name, he stands out for his work on antibody-drug conjugates, particularly those targeting the B7-H3 protein, which holds promise for various therapeutic applications.
Latest Patents
Yosup Rew's patent, titled "Antibody-drug conjugates comprising anti-B7-H3 antibodies," outlines a groundbreaking approach in cancer treatment. This patent focuses on antibody-drug conjugates (ADCs) that consist of an anti-B7-H3 antibody linked to one or more active agents through a specialized linker. This innovative design may allow for targeted delivery of therapeutic agents to cancer cells, enhancing treatment efficacy while reducing side effects. The patent also details the production methods of these monoclonal antibodies and their various therapeutic applications.
Career Highlights
Throughout his career, Yosup Rew has worked with notable companies such as Intocell, Inc. and Y-Biologics Inc. His experiences in these organizations have propelled advancements in biopharmaceuticals, particularly in the realm of targeted therapies. Rew’s expertise and dedication have garnered attention in the scientific community, firmly establishing him as an influential figure in his field.
Collaborations
During his professional journey, Yosup Rew has collaborated with talented individuals such as Taekyo Park and Sunyoung Kim. These partnerships have fostered a creative environment for innovation, allowing for the exploration of new therapeutic pathways and enhancing the development of antibody-based treatments.
Conclusion
In summary, Yosup Rew's contributions to the field of antibody-drug conjugates illustrate his commitment to advancing medical science. His patent on anti-B7-H3 antibodies signifies a step forward in targeted cancer therapies. As he continues to collaborate with esteemed colleagues, the potential for further groundbreaking discoveries in biotechnology remains promising.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile